Evaluation of the clinical and radiological.efficacy of recombinant human TNFR Ⅱ -Fc combined with methotrexate in the treatment of moderate and severe rheumatoid arthritis
Xiao-xiang CHEN,Qing DAI,Hua-xiang WU,Dong-bao ZHA,Xing-fu LI,Shao-xian HU,Nan-ping YANG,Yi TAO,Jian-hua XU,An-bin HUANG,Lin-di JIANG,Chun-de BAO
DOI: https://doi.org/10.3760/cma.j.issn.1007-7480.2011.10.004
2011-01-01
Abstract:Objective To evaluate the clinical and radiological efficacy of TNFR Ⅱ -Fc combined with methotrexate ( MTX ) in treatment of patients with moderate and severe rheumatoid arthritis.Methods Three hundred and ninty-six RA patients were randomized into the combined treatment group,the TNFR Ⅱ -Fc only group and MTX only group.All patients were treated for 24 weeks.ACR-N,ACR20,ACR50,ACR70,DAS28-ESR and Sharp score of both hands were measured for efficacy,and the side-effects were analyzed by one-way ANOVA.Results After 24-week therapy,the ACR-N of the combined treatment group [( 12.79±9.24)％-year] was significantly improved than that of the TNFR Ⅱ-Fc only group [(9.56±11.16)％-year,P＜0.05] and that of the MTX only group [(5.08±11.10)％-year,P＜0.05],and the TNFR Ⅱ-Fc group was significantly improved than that of the MTX group (P＜0.05).The ACR20 response rate of the combined group (80.4％) was significantly higher than that of the TNFR Ⅱ -Fc group (71.1％,P＜0.05) and the MTX group (56.7％,P＜0.01 ).The ACRS0 response rate of the combined group (53.6％) was significantly higher than that of the MTX group (30.8％,P＜0.01 ).The ACR70 response rate of the combined group was 27.7％,which was significantly different from that of the TNFR Ⅱ -Fc group (15.8％) and MTX group (7.7％,P＜0.05or P＜0.01 ).DAS28-ESR in the combination group was significantly reduced than those of the TNFR Ⅱ -Fc group and MTX group,and the DAS28-ESR of the TNFR Ⅱ -Fc group was significantly reduced than MTX group.The average total Sharp score of both hands,which demonstrated the radiographic changes,was significantly reduced in the combination group than the MTX group (P=0.03).The total adverse events in the combined group (40.9％) was significantly high than that of the MTX group (28.8％,P＜0.05).Conclusion TNFR Ⅱ -Fc combined with MTX can effectively control the activity of RA and radiological progress.